MOTS-c vs Semaglutide
Well Studied vs FDA Approved
synergistic Mechanism-based · 51% MOTS-c helps counteract the insulin-disrupting effects of Semaglutide. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
MOTS-c Semaglutide
Weight 2,174.6 Da 4,113.64 Da
Half-life ~30 minutes ~7 days (168 hours)
Chain 16 amino acids 31 amino acids
Type Mitochondrial-derived peptide (MDP) GLP-1 receptor agonist
Key Benefits
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
MOTS-c Semaglutide
Status Well Studied FDA Approved
References 5 studies 9 studies
Latest August 2025 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.